Advanced search
Publication Cover
Acta Oncologica Volume 60, 2021 - Issue 5
Journal homepage
1,319
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor: Clinical Onology

Primary pericardial mesothelioma: a case report of a patient treated with an immune checkpoint inhibitor as the second-line treatment

Otso Arponena Department of Radiology, Päijät-Häme Central Hospital, Lahti, Finland;b Faculty of Medicine and Health Technology, Tampere University, Tampere, FinlandCorrespondence[email protected]
,
Virpi Saloa Department of Radiology, Päijät-Häme Central Hospital, Lahti, Finland
,
Annika Lönnbergc Department of Cardiology, Päijät-Häme Central Hospital, Lahti, Finland
,
Leila Vaalavirtad Department of Oncology, Helsinki University Hospital, Helsinki, Finland
,
Hannu Koivue Department of Nuclear Medicine, Päijät-Häme Central Hospital, Lahti, Finland
&
Paul Nyandotod Department of Oncology, Helsinki University Hospital, Helsinki, Finland;f Department of Oncology, Päijät-Häme Central Hospital, Lahti, Finland
Pages 687-691 | Received 16 Dec 2020, Accepted 04 Feb 2021, Published online: 23 Feb 2021

References

  • Fine G. Primary tumor of the pericardium and heart. Cardiovasc. Clin. 1973;5:208.
  • McGehee E, Gerber DE, Reisch J, et al. Treatment and outcomes of primary pericardial mesothelioma: a contemporary review of 103 published cases. Clin Lung Cancer. 2019;20(2):e152–e157.
  • Gong W, Ye X, Shi K, et al. Primary malignant pericardial mesothelioma-a rare cause of superior vena cava thrombosis and constrictive pericarditis. J Thorac Dis. 2014;6(12):E272–e275.
  • Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–1414.
  • ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov Identifier: NCT02497508, Nivolumab in Patients With Recurrent Malignant Mesothelioma (NivoMes); 2015 June 14 [cited 2020 September 13]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02497508.
  • ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov Identifier: NCT02054806, Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28); 2014 February 4; [cited 2020 September 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02054806.
  • ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov Identifier: NCT02399371, Pembrolizumab in Treating Patients With Malignant Mesothelioma; 2015 March 26; [cited 2020 September 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02399371.
  • ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov Identifier: NCT02716272, Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (MAPS2); 2016 March 23; [cited 2020 September 10]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02716272.
  • ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov Identifier: NCT02784171, Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma; 2016 [cited 2020 September 10]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02784171.
  • Hotta K, Fujimoto N. Current evidence and future perspectives of immune checkpoint inhibitors in unresectable malignant pleural mesothelioma. J Immunother Cancer. 2020;8(1):e000461.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.